KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business OfficerRead More
BIOFIT, Strasbourg, France | November 29 – 30, 2022
Antibody Engineering & Therapeutics, San Diego, USA | December 4 – 8, 2022
BIO Partnering at JPM, San Francisco, USA | January 9 – 12, 2023
PepTalk, San Diego, USA | January 16 – 20, 2023
European Multispecific Antibody Cngress, Amsterdam, Netherlands | February 22 – 23, 2023
BioProcess International US West, San Diego, USA | February 27 – March 2, 2023
Interphex Week Osaka, Osaka, Japan | March 8 – 10, 2023
BIO-Europe Spring, Basel, Switzerland | March 20 – 22, 2023
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.